Cerebrolysin : The Next Evolution of Medicine

Product Information

Glial Cell Line-Derived Neurotrophic Factor: GDNF is a peptide in humans that promotes the survival of neurons and is made by the cells that support them. GDNF is especially important in protecting the neurons that produce dopamine and motor neurons. It has been shown to decrease the loss of neurons during development. It might potentially be useful in the treatment or prevention of Parkinson’s disease and amyotrophic lateral sclerosis (ALS). It is also important in regulating kidney and sperm development and has been shown to speed up the clearance of alcohol from the body. Guekht A, Vester J, Heiss W-D, Gusev E, Hoemberg V, Rahlfs VW, Bajenaru O, Popescu BO, Doppler E, Winter S, Moessler H, Muresanu D (2017) Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurol Sci 38(10):1761–1769. https://doi.org/10.1007/s10072-017-3037-z One of the most remarkable benefits of Cerebrolysin is its ability to noticeably improve cognitive function. After incorporating this supplement into my daily routine, I experienced enhanced focus, clarity, and mental stamina. Tasks that used to feel mentally draining now seem effortless, allowing me to accomplish more in less time. As practice shows, repeated and long-term courses of treatment with Cerebrolysin peptide lead to an increase in the effectiveness of neuro-therapy, especially in relation to improved cognitive and behavioral functions. Ziganshina et al (2016) Cerebrolysin for acute ischaemic stroke https://www.ncbi.nlm.nih.gov/pubmed/27918088

ii] Ghaffarpasand, F., Torabi, S., Rasti, A., Niakan, M. H., Aghabaklou, S., Pakzad, F., Beheshtian, M. S., & Tabrizi, R. (2018). Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsychiatric disease and treatment, 15, 127–135. https://doi.org/10.2147/NDT.S186865 Razavi S, Nazem G, Mardani M, Esfandiari E, Esfahani S, Salehi H (2015) Neurotrophic factors and their effects in the treatment of multiple sclerosis. Adv Biomed Res 4(1). https://doi.org/10.4103/2277-9175.151570 S. M. A. Hassanein, S. M. Deifalla, M. El-Houssinie, and S. A. Mokbel, “Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial,” J. Clin. Neurol. Seoul Korea, vol. 12, no. 1, pp. 79–84, Jan. 2016, doi: 10.3988/jcn.2016.12.1.79. Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M, Zhang ZG (2010) Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 88(15):3275–3281. https://doi.org/10.1002/jnr.22495 G. Ladurner, P. Kalvach, H. Moessler, and Cerebrolysin Study Group, “Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial,” J. Neural Transm. Vienna Austria 1996, vol. 112, no. 3, pp. 415–428, Mar. 2005, doi: 10.1007/s00702-004-0248-2.

Journals

All of the products will be handled only by qualified and properly trained RESEARCH or LABORATORY professionals only. Despite its prevalence and societal impact, there is no definitive, proven pharmacological treatment for VaD. Potential interventions may be considered at a number of levels: primary prevention, secondary prevention, symptomatic treatments, and disease‐modifying or curative approaches ( O'Brien 2006). The currently available data on the treatment of vascular risk factors does not prove a benefit in primary and secondary prevention ( Moorhouse 2008). Trials of monotherapies such as antiplatelet agent or statins for the prevention or treatment of VaD are also equivocal ( McGuinness 2014; O'Brien 2015; Chu 2018). Recent meta‐analysis of longitudinal Plosker GL, Gauthier S (2009) Cerebrolysin: a review of its use in dementia. Drugs Aging 26(11):893–915. https://doi.org/10.2165/11203320-000000000-00000 Asghari M, Meshkini A, Salehpoor F, Agazadeh J, Shakeri M, Shokohi G, Ebrahimi N, Bazzazi A, Pourhajshokr N (2014) Investigation of the effect of cerebrolysin on patients with head trauma and diffuse axonal injury. Int J Curr Res Acad Rev 2:62–69

Ren et al (2007) Cerebrolysin enhances functional recovery following focal cerebral infarction in rats https://www.ncbi.nlm.nih.gov/pubmed/17473393 There is also convincing research in the setting of cerebral palsy that indicates that Cerebrolysin can improve both cognitive and motor function following insult. In the latter, Cerebrolysin helps to increase the rate of gain of function in physical therapy. Long-term outcomes don’t actually differ, however, which is somewhat expected given that levels of neurotrophic factors are higher in kids and young adults[15], [16]. This classification is based on clinical differences and underlying pathologic changes. Although each category is well defined, in many cases it can be difficult to classify a patient into one definitive subtype. Subtypes are usually not pure. Rather, mixtures of pathologies frequently combine to contribute to cognitive impairment ( Moorhouse 2008).Xiao S, Xue H, Li G et al. (2012) Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. Aust N Z J Psychiatry 46, 153-160. Ziganshina LE, Abakumova T, Vernay L (2017) Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev 4(4):CD007026–CD007026. https://doi.org/10.1002/14651858.CD007026.pub5 Heiss (2012) Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial https://www.ncbi.nlm.nih.gov/pubmed/22282884 Stepanichev M, Onufriev M, Aniol V, Freiman S, Brandstaetter H, Winter S, Lazareva N, Guekht A, Gulyaeva N (2017) Effects of cerebrolysin on nerve growth factor system in the aging rat brain. Restor Neurol Neurosci 35(6):571–581. https://doi.org/10.3233/rnn-170724

Another significant advantage of Cerebrolysin is its neuroprotective properties. By protecting neurons from damage and promoting their growth, this supplement may help prevent age-related cognitive decline. This makes it an excellent choice for individuals looking to maintain their mental sharpness as they age. Muresanu et al (2008) A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration https://www.ncbi.nlm.nih.gov/pubmed/18048059 S. Gauthier, J. Proaño, J. Jia, L. Froelich, J. Vester, and E. Doppler, “Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.,” Dement Geriatr Cogn Disord, vol. 39, no. 5–6, 2015, doi: 10.1159/000377672. W. H. Chang et al., “Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke,” BMC Neurol., vol. 16, p. 31, Mar. 2016, doi: 10.1186/s12883-016-0553-z. Clinical studies showed that Cerebrolysin is a very safe product and well-tolerated in most patients. No evidence of allergy or anaphylactic reaction has been documented regarding Cerebrolysin. However, minimal side effects can occur which are usually temporary and resolve within 2-3 days. Common side effects include the following:

Sharma HS, Zimmermann-Meinzingen S, Johanson CE (2010) Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat. Ann N Y Acad Sci 1199:125–137. https://doi.org/10.1111/j.1749-6632.2009.05329.x Gavrilova SI, Alvarez A (2020) Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use. Med Res Rev. https://doi.org/10.1002/med.21722 Vereshchagin NV, Nekrasova EM, Lebedeva NV, Suslina ZA, Solov'ev OI, Piradov MA, Altunina MN. Legkie formy mul'tiinfarktnoĭ dementsii: éffektivnost' tserebrolizina [Mild forms of multi-infarct dementia: effectiveness of cerebrolysin]. Sov Med. 1991;(11):6–8. Russian. PMID: 1767322 Bornstein N, Poon WS (2012) Accelerated recovery from acute brain injuries: clinical efficacy of neurotrophic treatment in stroke and traumatic brain injuries. Drugs Today (Barc) 48(Suppl A):43–61. https://doi.org/10.1358/dot.2012.48(Suppl.A).1739723